

Eliahu Heldman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8168964/publications.pdf>

Version: 2024-02-01

64
papers

2,796
citations

218677

26
h-index

168389

53
g-index

64
all docs

64
docs citations

64
times ranked

3312
citing authors

#	ARTICLE	IF	CITATIONS
1	Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2009, 26, 523-580.	2.2	761
2	Anandamide, a Brain Endogenous Compound, Interacts Specifically with Cannabinoid Receptors and Inhibits Adenylate Cyclase. <i>Journal of Neurochemistry</i> , 1993, 61, 352-355.	3.9	281
3	Multifunctional RNA Nanoparticles. <i>Nano Letters</i> , 2014, 14, 5662-5671.	9.1	181
4	Discrete activation of transduction pathways associated with acetylcholine m1 receptor by several muscarinic ligands. <i>European Journal of Pharmacology</i> , 1994, 267, 21-31.	2.6	121
5	Mitogen-Activated Protein Kinase-Dependent and Protein Kinase C-Dependent Pathways Link the m1 Muscarinic Receptor to β -Amyloid Precursor Protein Secretion. <i>Journal of Neurochemistry</i> , 1998, 71, 2094-2103.	3.9	111
6	Activation of different split functionalities on re-association of RNA-DNA hybrids. <i>Nature Nanotechnology</i> , 2013, 8, 296-304.	31.5	106
7	Digitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosis lung epithelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 7693-7698.	7.1	87
8	M1 Agonists for the Treatment of Alzheimer's Disease.. <i>Annals of the New York Academy of Sciences</i> , 1996, 777, 189-196.	3.8	64
9	Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. <i>European Journal of Pharmacology</i> , 1995, 287, 145-152.	3.5	61
10	Lipopolysaccharide-induced production of tumor necrosis factor activity in rats with and without risk factors for stroke. <i>Brain Research</i> , 1991, 541, 115-120.	2.2	51
11	Amyloid Precursor Protein Secretion via Muscarinic Receptors: Reduced Desensitization Using the M1-Selective Agonist AF102B. <i>Biochemical and Biophysical Research Communications</i> , 1994, 203, 652-658.	2.1	47
12	Muscarinic control of amyloid precursor protein secretion in rat cerebral cortex and cerebellum. <i>Brain Research</i> , 1996, 742, 299-304.	2.2	47
13	Reversible and Irreversible Inhibition of High-Affinity Choline Transport Caused by Ethylcholine Aziridinium Ion. <i>Journal of Neurochemistry</i> , 1987, 49, 468-474.	3.9	46
14	In Silico, In Vitro, and In Vivo Studies Indicate the Potential Use of Bolaamphiphiles for Therapeutic siRNAs Delivery. <i>Molecular Therapy - Nucleic Acids</i> , 2013, 2, e80.	5.1	46
15	Delivery of proteins to the brain by bolaamphiphilic nano-sized vesicles. <i>Journal of Controlled Release</i> , 2012, 160, 315-321.	9.9	43
16	Inhibition of specific adenylyl cyclase isoforms by lithium and carbamazepine, but not valproate, may be related to their antidepressant effect. <i>Bipolar Disorders</i> , 2009, 11, 885-896.	1.9	40
17	Cationic vesicles from novel bolaamphiphilic compounds. <i>Journal of Liposome Research</i> , 2010, 20, 147-159.	3.3	39
18	Bolaamphiphiles as carriers for siRNA delivery: From chemical syntheses to practical applications. <i>Journal of Controlled Release</i> , 2015, 213, 142-151.	9.9	39

#	ARTICLE	IF	CITATIONS
19	NGF Promotes Amyloid Precursor Protein Secretion via Muscarinic Receptor Activation. <i>Biochemical and Biophysical Research Communications</i> , 1995, 213, 15-23.	2.1	37
20	Delivery of analgesic peptides to the brain by nano-sized bolaamphiphilic vesicles made of monolayer membranes. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 85, 381-389.	4.3	36
21	Ultrastructure of photoreceptors in the eye of <i>Hermissenda</i> labelled with intracellular injections of horseradish peroxidase. <i>Journal of Neurocytology</i> , 1979, 8, 181-195.	1.5	34
22	Asymmetric bolaamphiphiles from vernonia oil designed for drug delivery. <i>European Journal of Lipid Science and Technology</i> , 2010, 112, 137-151.	1.5	34
23	Distinct Muscarinic Receptor Subtypes Differentially Modulate Acetylcholine Release from Corticocerebral Synaptosomes. <i>Journal of Neurochemistry</i> , 1990, 55, 665-672.	3.9	32
24	A novel immunoassay with direct relevance to protection against organophosphate poisoning. <i>FEBS Letters</i> , 1985, 180, 243-248.	2.8	31
25	Lithium preferentially inhibits adenylyl cyclase V and VII isoforms. <i>International Journal of Neuropsychopharmacology</i> , 2008, 11, 533-9.	2.1	31
26	Selective Signaling via Unique M1 Muscarinic Agonists. <i>Annals of the New York Academy of Sciences</i> , 1993, 695, 300-303.	3.8	27
27	Bolaamphiphilic vesicles encapsulating iron oxide nanoparticles: New vehicles for magnetically targeted drug delivery. <i>International Journal of Pharmaceutics</i> , 2013, 450, 241-249.	5.2	26
28	Ectopic ATP synthase facilitates transfer of HIV-1 from antigen-presenting cells to CD4+ target cells. <i>Blood</i> , 2012, 120, 1246-1253.	1.4	25
29	Pharmacological basis for functional selectivity of partial muscarinic receptor agonists. <i>European Journal of Pharmacology</i> , 1996, 297, 283-291.	3.5	24
30	Characterization of Cationic Bolaamphiphile Vesicles for siRNA Delivery into Tumors and Brain. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 20, 359-372.	5.1	24
31	Dehydroepiandrosterone (DHEA) increases production and release of Alzheimer's amyloid precursor protein. <i>Life Sciences</i> , 1996, 59, 1651-1657.	4.3	20
32	Site-directed decapsulation of bolaamphiphilic vesicles with enzymatic cleavable surface groups. <i>Journal of Controlled Release</i> , 2012, 160, 306-314.	9.9	20
33	NGF-dependent neurotrophic-like effects of AF102B, an M1 Muscarinic agonist, in PC12M1 cells. <i>NeuroReport</i> , 1995, 6, 485-488.	1.2	19
34	Effects of α 2-Adrenergic Agonists and Antagonists on Photoreceptor Membrane Currents. <i>Journal of Neurochemistry</i> , 1987, 48, 405-416.	3.9	18
35	Progress in Lipid-Based Nanoparticles for Cancer Therapy. <i>Critical Reviews in Oncogenesis</i> , 2014, 19, 247-260.	0.4	18
36	Cholinotoxicity of the ethylcholine aziridinium ion in primary cultures from rat central nervous system. <i>Brain Research</i> , 1988, 454, 298-307.	2.2	17

#	ARTICLE	IF	CITATIONS
37	Dehydroepiandrosterone Augments M1-Muscarinic Receptor-Stimulated Amyloid Precursor Protein Secretion in Desensitized PC12M1 Cells. <i>Annals of the New York Academy of Sciences</i> , 1995, 774, 300-303.	3.8	15
38	Novel m1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease: An unifying hypothesis. <i>Journal of Physiology (Paris)</i> , 1998, 92, 337-340.	2.1	14
39	Interfacial and self-assembly properties of bolaamphiphilic compounds derived from a multifunctional oil. <i>Journal of Colloid and Interface Science</i> , 2012, 365, 53-62.	9.4	14
40	Expression and localization of muscarinic receptors in P19-derived neurons. <i>Journal of Molecular Neuroscience</i> , 1998, 10, 17-29.	2.3	12
41	The role of neurochemical modulation in learning. <i>Neuroscience Research</i> , 1986, 3, 487-497.	1.9	11
42	Extracellular matrix permits the expression of von willebrand's factor, uptake of Di-I-acetylated low density lipoprotein and secretion of prostacyclin in cultures of endothelial cells from rat brain microvessels. <i>In Vitro Cellular & Developmental Biology</i> , 1991, 27, 689-697.	1.0	10
43	Rigid analogs of acetylcholine can be m1-selective agonists: implications for a rational treatment strategy in Alzheimer's disease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1992, 2, 839-844.	2.2	10
44	Agonist-stimulated release of von Willebrand factor and procoagulant factor VIII in rats with and without risk factors for stroke. <i>Brain Research</i> , 1994, 647, 265-272.	2.2	10
45	Neurotransmitter synthesis in the nervous system of the mollusc <i>Hermissenda</i> . <i>Comparative Biochemistry and Physiology Part C: Comparative Pharmacology</i> , 1978, 59, 117-125.	0.2	7
46	Osmotic strength differentiates between two types of calcium transport pathways regulating catecholamine secretion from cultured bovine chromaffin cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1991, 1091, 417-425.	4.1	7
47	Steric environment around acetylcholine head groups of bolaamphiphilic nanovesicles influences the release rate of encapsulated compounds. <i>International Journal of Nanomedicine</i> , 2014, 9, 561.	6.7	7
48	Cholinotoxicity induced by ethylcholine aziridinium ion after intracarotid and intracerebroventricular administration. <i>Life Sciences</i> , 1989, 44, 1437-1448.	4.3	6
49	Inhibition of choline efflux results in enhanced acetylcholine synthesis and release in the guinea-pig corticocerebral synaptosomes. <i>Neurochemistry International</i> , 1992, 20, 219-227.	3.8	6
50	Differential long-term effect of AF64A on [3H]ACh synthesis and release in rat hippocampal synaptosomes. <i>Brain Research</i> , 1992, 586, 148-151.	2.2	6
51	Comparison of stimulated tissue factor expression by brain microvascular endothelial cells from normotensive (WKY) and hypertensive (SHR) rats. <i>Brain Research</i> , 1992, 597, 346-349.	2.2	4
52	Selective Signaling Via Novel Muscarinic Agonists: Implications for Alzheimer's Disease Treatments and Clinical Update. , 1994, , 219-223.		4
53	New M1 Agonists: Selective Signaling, Neurotrophic-Like and Cognitive Effects - Implications in the Treatment of Alzheimer's Disease. <i>Advances in Behavioral Biology</i> , 1995, , 449-455.	0.2	3
54	Optimization of analytical methods based on non-linear asymptotic calibration graphs. <i>Analytica Chimica Acta</i> , 1982, 144, 55-72.	5.4	2

#	ARTICLE	IF	CITATIONS
55	Newly synthesized bolaamphiphiles from castor oil and their aggregated morphologies for potential use in drug delivery. <i>Tetrahedron</i> , 2015, 71, 8557-8571.	1.9	2
56	(+)-Cis-Methyl-Spiro(1,3-Oxathiolane-5,3-Quinuclidine (AF102B): A New M1 Agonist as a Rational Treatment Strategy in Alzheimer's Disease - An Overview. <i>Advances in Behavioral Biology</i> , 1990, , 309-319.	0.2	2
57	Molecular Dynamics Simulations of siRNA Bolaamphiphile Nanoparticle Complexes Suggest Their Potential as a Therapeutic siRNA Delivery Vehicle. <i>Biophysical Journal</i> , 2011, 100, 472a.	0.5	0
58	In Silico and in Ex-Vivo Experiments Indicate the Potential of Nanoparticles Composed of RNA-Bolaamphiphile Complexes as a Therapeutic siRNA Delivery Vehicle. <i>Biophysical Journal</i> , 2012, 102, 638a.	0.5	0
59	In-Silico, In-Vitro, and In-Vivo Studies of Sirna Delivery using Cationic Bolaamphiphile Vesicles. <i>Biophysical Journal</i> , 2018, 114, 436a.	0.5	0
60	New Muscarinic Agonists with Special Emphasis on AF102B. , 1991, , 354-362.		0
61	Novel M1 Agonists: From Symptomatic Treatment Towards Delaying the Progression of Alzheimer's Disease. , 1997, , 317-322.		0
62	Muscarinic Modulation of β -Amyloid Precursor Protein (β App) Processing in Vitro and in Vivo. <i>Advances in Behavioral Biology</i> , 1998, , 509-513.	0.2	0
63	M1 Muscarinic Agonists: From Treatment Toward Delaying Progression of Alzheimer's Disease. <i>Advances in Behavioral Biology</i> , 1998, , 515-522.	0.2	0
64	Quaternary-Lipophilic Carbamates with Blood Brain Barrier Permeability as Potential Drugs for Memory Impairment Associated with Cholinergic Deficiency. <i>Advances in Behavioral Biology</i> , 1998, , 595-600.	0.2	0